Germline TP53 pathogenic variants are rare and predispose to early onset breast cancer which, in combination with other tumour types such as malignant brain tumours and sarcoma, is recognised clinically as a manifestation of Li–Fraumeni syndrome (LFS) 3, 4. This evidence concerns the gene TP53 and neoplasm.